Picture of Devyser Diagnostics AB logo

DVYSR Devyser Diagnostics AB News Story

0.000.00%
se flag iconLast trade - 00:00
HealthcareAdventurousSmall CapFalling Star

Sweden's Devyser Q1 net sales rise 12.9%, operating profit turns positive

Overview

Sweden diagnostics kit maker's Q1 net sales rose 12.9% yr/yr; operating profit positive

Company cites US academic sector headwinds, geopolitical uncertainty, and currency fluctuations as challenges

Devyser completed CyberGene AB acquisition after quarter, expected to boost gross profit and margin

Outlook

Company expects CyberGene AB acquisition to positively impact gross profit and gross margin

Company cites ongoing headwinds in US academic sector and unfavorable currency fluctuations

Company notes geopolitical uncertainty linked to the war in the Middle East as a challenge

Result Drivers

ORGANIZATIONAL EFFICIENCY - Co said improved growth, margin and cash flow reflect a more efficient organization and business model

NEW PRODUCT LAUNCH - Launch of first IVDR-compatible NGS assay for thalassemia and sickle cell anemia contributed to product portfolio expansion

SUPPLY AGREEMENT - Strategic supply agreement with Illumina enabled offering of sequencing instruments with Devyser’s reagent solutions

Company press release: ID:nMFN6tkxKn

Key Details

MetricBeat/MissActualConsensus Estimate
Q1 SalesSEK 61.80 mln
Q1 Adjusted EPSSEK 0.17
Q1 Net IncomeSEK 2.90 mln
Q1 Adjusted Free Cash FlowSEK 12.10 mln
Q1 EBITSEK 2.60 mln
Analyst Coverage The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell" The average consensus recommendation for the biotechnology & medical research peer group is "buy" Wall Street's median 12-month price target for Devyser Diagnostics AB is SEK164.00, about 83.2% above its April 24 closing price of SEK89.50 The stock recently traded at 29 times the next 12-month earnings vs. a P/E of 44 three months ago For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com. (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Devyser Diagnostics AB

See all news